Edition:
United Kingdom

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.86USD
14 Dec 2017
Change (% chg)

$0.01 (+0.35%)
Prev Close
$2.85
Open
$2.86
Day's High
$3.02
Day's Low
$2.85
Volume
103,408
Avg. Vol
146,605
52-wk High
$5.28
52-wk Low
$2.24

Summary

Name Age Since Current Position

David Guyer

57 2017 Executive Chairman of the Board

Glenn Sblendorio

61 2017 President, Chief Executive Officer

David Carroll

51 2017 Chief Financial Officer, Senior Vice President, Treasurer

Keith Westby

42 2017 Chief Operating Officer, Senior Vice President

Barbara Wood

54 2015 Senior Vice President, General Counsel, Secretary

David Redlick

67 2016 Lead Independent Director

Axel Bolte

45 2007 Independent Director

Thomas Dyrberg

63 2007 Independent Director

Michael Ross

67 2013 Independent Director

Kathy Galante

2017 Vice President, Investor Relations and Corporate Communications

Biographies

Name Description

David Guyer

Dr. David R. Guyer, M.D. is Executive Chairman of the Board of Ophthotech Corporation. Prior to serving as our Chief Executive Officer, Dr. Guyer, served as a Partner at SV Life Sciences Advisers, LLC, a venture capital firm, from 2009 to 2013, and as a Venture Partner at SV Life Sciences from 2006 to 2009. In April 2013, Dr. Guyer resumed his role as Venture Partner at SV Life Sciences. He currently serves on the board of directors of Thrombogenics NV, a publicly traded biopharmaceutical company, and Applied Genetic Technologies Corporation, a publicly traded biotechnology company. Dr. Guyer co-founded Eyetech Pharmaceuticals Inc. and served as Chief Executive Officer and as a member of its board of directors from 2000 to 2006. Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a Professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Glenn Sblendorio

Mr. Glenn P. Sblendorio serves as President, Chief Executive Officer of the Company. He was Chief Operating Officer, Executive Vice President of the Company. Mr. Sblendorio previously served as the Company’s Executive Vice President and Chief Operating Officer from April 1, 2016 to January 29, 2017, during which time he also served as Chief Financial Officer and Treasurer. Mr. Sblendorio served as a member of the Company’s Board of Directors (the “Board”) from July 2013 through March 2016. Prior to joining the Company, Mr. Sblendorio served as the President and Chief Financial Officer of The Medicines Company, a publicly traded medical solutions company, from March 2006 until December 2015. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development at The Medicines Company. Mr. Sblendorio currently serves as a member of the board of directors of Intercept Pharmaceuticals, Inc. and Amicus Therapeutics Inc., both of which are publicly traded biopharmaceutical companies, and previously served on the board of directors of The Medicines Company, as well as Ophthotech. Mr. Sblendorio received a B.B.A. from Pace University and an M.B.A. from Fairleigh Dickinson University.

David Carroll

Mr. David Carroll is Chief Financial Officer, Senior Vice President, Treasurer of the Company. Mr. Carroll, was appointed Senior Vice President, Chief Financial Officer and Treasurer of the Company. Mr. Carroll joined the Company in June 2016 and previously served as Senior Vice President, Finance from June 2016 to April 2017. Prior to joining the Company, Mr. Carroll served in several senior financial leadership roles at The Medicines Company from to May 2008 to June 2016, including Vice President, Controller from October 2008 to December 2015 and Senior Vice President, Chief Accounting Officer from January 2016 to June 2016. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Inc., a member of the Roche Group, Novartis AG, and Bristol-Myers Squibb Company. Mr. Carroll is a certified public accountant and received a B.A. in Economics from Ursinus College and an M.B.A. from Rutgers University.

Keith Westby

Mr. Keith Westby serves as Chief Operating Officer, Senior Vice President of the Company. Mr. Westby joined the Company in 2007 and previously served as Senior Vice President of Development Operations from October 2014 to January 2017, as Vice President, Program Management and Business Operations from December 2012 to September 2014 and Senior Director, Project Management from August 2007 to December 2012. Prior to joining the Company, Mr. Westby served as Director, Project and Alliance Management at Pharmasset, Inc., a pharmaceutical company, from December 2005 to August 2007. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, Inc. from January 2002 to December 2005, including Director, Alliance & Project Management. Earlier in his career, Mr. Westby worked at Tunnell Consulting as a Senior Consultant. Mr. Westby received a B.S. in Physics from the State University of New York, College at Geneseo, an M.S. in Engineering Management from Drexel University and an M.B.A. from Columbia Business School.

Barbara Wood

Ms. Barbara A. Wood, Esq. is Senior Vice President, General Counsel, Secretary of Ophthotech Corporation. Prior to joining us, Ms. Wood practiced law at Wood Legal, from January 2011 to November 2013. From April 2001 to December 2010, Ms. Wood served in varying roles at OSI Pharmaceuticals, Inc., most recently as Senior Vice President, General Counsel and Secretary. Before joining OSI, Ms. Wood was a partner at the New York firm of Squadron, Ellenoff, Plesent & Sheinfeld (now part of Hogan Lovells), focusing on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. Ms. Wood received her B.A. in Economics and Classics from Connecticut College and her J.D. from Columbia Law School.

David Redlick

Mr. David E. Redlick is Lead Independent Director of Ophthotech Corporation. Mr. Redlick has served as a special advisor at Leerink Partners LLC, an investment bank focused on the healthcare industry, since January 2015. Previously, Mr. Redlick worked at Wilmer Cutler Pickering Hale and Dorr LLP, an international law firm for over 40 years, serving as a Partner in the Corporate Practice Group until December 2014, and as Senior Counsel from January 2015 to December 2015. During his career at WilmerHale, Mr. Redlick also served as the co-chair of the Life Sciences Group, the co-chair of the Corporate Department and a member of the firm's Executive Committee. Mr. Redlick received a B.A. from the University of Wisconsin and a J.D. from Harvard Law School. We believe that Mr. Redlick is qualified to serve on our board of directors because of his extensive leadership experience and experience advising life sciences companies.

Axel Bolte

Mr. Axel Bolte is Independent Director of Ophthotech Corporation. Since March 2003, Mr. Bolte has served as investment advisor to HBM Partners AG, a provider of investment advisory services in the life sciences industry. From March 2001 to February 2003, Mr. Bolte was an investment manager of NMT New Medical Technologies AG, a Swiss venture capital company focused on life sciences. Prior to joining NMT New Medical Technologies AG, Mr. Bolte served as a scientist at Serono SA, a biotechnology company. Mr. Bolte has also served on the board of directors of PTC Therapeutics, Inc., a publicly traded biotechnology company. Mr. Bolte received a degree in Biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland.

Thomas Dyrberg

Dr. Thomas Dyrberg, M.D., is Independent Director of Ophthotech Corporation. Dr. Dyrberg joined Novo A/S, a limited liability company wholly-owned by the Novo Nordisk Foundation that is responsible for managing the Foundation's assets, where he serves as a Senior Partner. In 1990, Dr. Dyrberg joined Novo Nordisk A/S, initially working in Health Care Discovery. From 1996 to 2000, he served as an International Clinical Project Manager at Novo Nordisk A/S. Dr. Dyrberg serves on the board of directors of Veloxis A/S, a publicly traded specialty pharmaceutical company. Dr. Dyrberg received a D.M.Sc. and an M.D. from the University of Copenhagen. Dr. Dyrberg has held research positions at the Hagedorn Research Institute in Denmark, and at the Scripps Research Institute in California.

Michael Ross

Dr. Michael Jay Ross, Ph.D. is Independent Director of Ophthotech Corporation. Dr. Ross has served as a Managing Partner at SV Life Sciences, a venture capital firm, since January 2001. Dr. Ross served as a Managing Partner at Didyma, LLC, a biotechnology management consulting firm, from 1999 to 2002. Previously, Dr. Ross served as the Chief Executive Officer of CyThera, Inc., Carta Proteomics Inc., MetaXen LLC and Arris Pharmaceutical Corporation. Earlier in his career, Dr. Ross was employed at Genentech, serving in several roles, including Vice President of Development and later Vice President of Medicinal and Biomolecular Chemistry. Dr. Ross serves on the board of overseers of the Thayer School of Engineering at Dartmouth College. Dr. Ross received an A.B. from Dartmouth College, a Ph.D. in chemistry from the California Institute of Technology and completed post doctorate training in molecular biology at Harvard University.

Kathy Galante

Ms. Kathy Galante is Vice President of Investor Relations and Corporate Communications at Ophthotech Corporation. She has more than 25 years of investor and public relations experience in the biotechnology industry with OSI Pharmaceuticals and Burns McClellan. For 23 years, Ms. Galante led OSI Pharmaceuticals’ (now Astellas Pharma) investor relations efforts as the company transformed from a small, $200 million research-based biotechnology company into a profitable, $4 billion biopharmaceutical organization with discovery, development and commercialization capabilities. Following OSI, Ms. Galante was Senior Vice President of Investor Relations at Burn McClellan.

Basic Compensation

Name Fiscal Year Total

David Guyer

8,700,990

Glenn Sblendorio

8,890,150

David Carroll

--

Keith Westby

--

Barbara Wood

2,082,640

David Redlick

--

Axel Bolte

--

Thomas Dyrberg

12,500

Michael Ross

333,573

Kathy Galante

--
As Of  31 Dec 2016

Options Compensation